Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
I-ATTAC: DC Vaccine in Glioblastoma
NCT03927222Phase 2Terminated
- Start
- Sep 2019
- Primary completion
- Feb 2023
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pp65-shLAMP DC in glioblastoma (GBM). Primary endpoint: Median Overall Survival. Started Sep 2019; status: terminated.
02
Drugs
pp65-shLAMP DC
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03927222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03927222.